首页 工具
登录
购物车
CY-09

CY-09

产品编号 T4164   CAS 1073612-91-5
别名: CY 09

CY-09 是NLRP3选择性抑制剂。它能够直接与 NLRP3 NACHT 结构域的 ATP 结合基序结合,对 NLRP3 ATP 酶的活性产生抑制作用,进而抑制 NLRP3 炎症小体的组装和活化。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
CY-09 Chemical Structure
CY-09, CAS 1073612-91-5
规格 价格/CNY 货期 数量
1 mg ¥ 413 现货
5 mg ¥ 745 现货
10 mg ¥ 1,330 现货
25 mg ¥ 2,890 现货
50 mg ¥ 4,270 现货
100 mg ¥ 5,970 现货
1 mL * 10 mM (in DMSO) ¥ 822 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
Doxorubicin hydrochloride限时半价
产品目录号及名称: CY-09 (T4164)
点击图片重新获取验证码
选择批次  
纯度: 100%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 CY-09 is an NLRP3 inhibitor.
体外活性 CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 and MCC950 specifically inhibit NLRP3 inflammasome activation and have no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization
体内活性 Compare with MCC950, CY-09 treatment?in vivo?efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation?in vivo. CY-09 treatment also increases the survival of?NLRP3mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of HFD-treated mice is also suppressed by CY-09
激酶实验 For ATPase activity assay, purified recombinant human proteins are incubated at 37°C with indicated concentrations of CY-09 for 15 min in the reaction buffer. ATP (25 μM) is then added, and the mixture is further incubated at 37°C for another 40 min. The amount of ATP converted into adenosine diphosphate (ADP) is determined by luminescent ADP detection with ADP-Glo Kinase Assay kit according to the manufacturer's protocol. The results are expressed as percentage of residual enzyme activity to the vehicle-treated enzyme. For ATP binding assay, purified NLRP3 proteins are incubated with ATP binding agarose for 1 h and then different concentrations of CY-09 are added and incubated for 2 h with motion at 4°C. Beads are washed and boiled in loading buffer. Samples are subjected to immunoblotting analysis[1].
细胞实验 To induce NLRP3 inflammasome activation, 5×105/mL BMDMs and 6×106/mL PBMCs are plated in 12-well plates. The following morning, the medium is replaced, and cells are stimulated with 50 ng/mL LPS or 400 ng/mL Pam3CSK4 (for noncanonical inflammasome activation) for 3 h. After that, CY-09 or other inhibitors are added into the culture for another 30 min, and then the cells are stimulated for 4 h with monosodium urate (MSU) (150 μg/mL),?Salmonella typhimurium?(multiplicity of infection) or for 30 min with ATP (2.5 mM) or nigericin (10 μM). Cells are transfected with poly(dA:dT) (0.5 μg/mL) for 4 h or LPS (500 ng/mL) overnight. Cell extracts and precipitated supernatants are analyzed by immunoblot[1].
动物实验 For the?in vivo?experiments, CY-09 is formulated in a vehicle containing 10% DMSO, 10% Solutol HS 15, and 80% saline,WT or Nlrp3?/? mice at the age of 6 wk, with similar plasma glucose levels and body weights are randomized into different groups. For generation of high-fat diet (HFD)-induced diabetic mice, mice are fed with HFD for 14 wk. The diabetic mice are treated with CY-09 (i.p.) at a dose of 2.5 mg/kg once a day for 6 wk. The mice are maintained with HFD when used for CY-09 treatment and the subsequent experiments[1].
别名 CY 09
分子量 423.43
分子式 C19H12F3NO3S2
CAS No. 1073612-91-5

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 77 mg/mL(181.8 mM)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3617 mL 11.8083 mL 23.6167 mL 59.0416 mL
5 mM 0.4723 mL 2.3617 mL 4.7233 mL 11.8083 mL
10 mM 0.2362 mL 1.1808 mL 2.3617 mL 5.9042 mL
20 mM 0.1181 mL 0.5904 mL 1.1808 mL 2.9521 mL
50 mM 0.0472 mL 0.2362 mL 0.4723 mL 1.1808 mL
100 mM 0.0236 mL 0.1181 mL 0.2362 mL 0.5904 mL

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214(11):3219-3238. 2. Jia Y, Cui R, Wang C, et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway[J]. Redox Biology. 2020: 101534. 3. Chen Z, Zhang S, Nie B, et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway[J]. Redox Biology. 2020: 101534.

TargetMol Library Books文献引用

1. Jia Y, Cui R, Wang C, et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway. Redox Biology. 2020: 101534. 2. Jia Y, Cui R, Wang C, et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway. Redox Biology. 2020: 101534. 3. Zhang Y, Liu Y, Xie Z, et al.Inhibition of PFKFB Preserves Intestinal Barrier Function in Sepsis by Inhibiting NLRP3/GSDMD.Oxidative Medicine and Cellular Longevity.2022, 2022. 4. Zhu Q, Zheng F, You W, et al.Expression of histone H1 in rats with traumatic brain injury and the effect of the NLRP3 inflammasome pathway.World Neurosurgery.2022
D359-0396 NLRP3 agonist 1 NLRP3-IN-22 NLRP3 agonist 2 Ruscogenin Arglabin Nodinitib-1 INF200

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 抗卵巢癌化合物库 细胞焦亡化合物库 HIF-1化合物库 已知活性化合物库 免疫/炎症分子化合物库 抗肝癌化合物库 NF-κB 通路分子库 经典已知活性库 抗糖尿病库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

CY-09 1073612-91-5 Immunology/Inflammation NF-Κb NOD-like Receptor (NLR) NOD CY09 Inhibitor inhibit CY 09 inhibitor

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼